Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1997-11-21
1999-04-06
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514171, 514947, 424443, 424449, 424448, A31K 3156, A61F 1300
Patent
active
058918680
ABSTRACT:
The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present invention.
REFERENCES:
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3797494 (1974-03-01), Zaffaroni
patent: 4031894 (1977-06-01), Urquhart et al.
patent: 4460372 (1984-07-01), Campbell et al.
patent: 4573996 (1986-03-01), Kwiatek et al.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4722941 (1988-02-01), Eckert et al.
patent: 5223261 (1993-06-01), Nelson et al.
patent: 5460820 (1995-10-01), Ebert et al.
Ettinger, B. et al., "Long-Term Estrogen Replacement Therapy Prevents Bone Loss and Fractures," Ann. Int. Med. 102:319-324 (1985).
Ettinger, B. et al., "Postmenopausal Bone Loss is Prevented by Treatment with Low-Dosage Estrogen with Calcium," Ann. Int. Med. 106:40-45 (1987).
Ettinger, B. et al., "Low-dosage micronized 17.beta.-estradiol prevents bone loss in postmenopausal women," Am. J. Obst. Gyn. 166(2):479-488 (1992).
Evans, S.F. et al., "Low and conventional dose transdermal oestradiol are equally effective at preventing bone loss in spine and femur at all postmenopausal ages," Clin. Endo. 44:79-84 (1996).
Hillard, T.C. et al., "Long-Term Effects of Transdermal and Oral Hormone Replacement Therapy on Postmenopausal Bone Loss," Osteoporosis Int. 4:341-348 (1994).
Horsman, A. et al., "The Effect of Estrogen Dose on Postmenopausal Bone Loss," N. Engl. J. Med. 309(23):1405-1407 (1983).
Lindsay, R. et al., "The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss," Obst. Gyn. 63(6):759-763 (1984).
Naessen, T. et al., "Bone loss in elderly women prevented by ultralow doses of parental 17.beta.-estradiol," Am. J. Obst. Gyn. 177(1):115-119 (1997).
Stevenson, J.C. et al., "Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women," The Lancet 336:265-269 (1990).
Tepper, R. et al., "Estrogen Replacement in Postmenopausal Women: Are We Currently Overdosing Our Patients," Gyn. Obst. Invest. 38:113-116 (1994).
Cummings Steven
Ellman Herman
Ettinger Bruce
Berlex Laboratories
Criares Theodore J.
Kaiser Foundation Health Plan, Inc.
Permanente Medical Group, Inc.
The Regents of the University of California
LandOfFree
Methods for treating postmenopausal women using ultra-low doses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating postmenopausal women using ultra-low doses , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating postmenopausal women using ultra-low doses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1371501